The aim of this study was to evaluate the risk of mortality according to the presence of metabolic syndrome in chronic obstructive pulmonary disease (COPD) patients who were followed for 5 years. We did not establish the influence of metabolic syndrome on mortality rate. However, an increase of 100 mg of triglycerides was associated with a 39% increase in the probability of death in the period of the study (hazard ratio 1.39, 95% confidence interval 1.06–1.83).
Get full access to this article
View all access options for this article.
References
1.
Diez-ManglanoJ, Barquero-RomeroJ, AlmagroP, et al.COPD patients with and without metabolic syndrome: Clinical and functional differences. Intern Emerg Med, 2013; 5:5.
2.
LamKB, JordanRE, JiangCQ, et al.Airflow obstruction and metabolic syndrome: The Guangzhou Biobank Cohort Study. Eur Respir J, 2010; 35:317–323.
3.
MarquisK, MaltaisF, DuguayV, et al.The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil, 2005; 25:226–232; discussion 233–234.
4.
PaekYJ, JungKS, HwangYI, et al.Association between low pulmonary function and metabolic risk factors in Korean adults: The Korean National Health and Nutrition Survey. Metabolism., 2010; 59:1300–1306.
5.
KupeliE, UlubayG, UlasliSS, et al.Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: A preliminary study. Endocrine, 2010; 38:76–82.
6.
GOLD. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary update, 2013. Available at www.goldcopd.org
7.
CelliBR, CoteCG, MarinJM, et al.The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004; 350:1005–1012.
8.
AlbertiKG, EckelRH, GrundySM, et al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120:1640–1645.
9.
FunakoshiY, OmoriH, MiharaS, et al.Association between airflow obstruction and the metabolic syndrome or its components in Japanese men. Intern Med, 2010; 49:2093–2099.
10.
BreyerMK, SpruitMA, HansonCK, et al.Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One, 2014; 9:e98013.
11.
Ghaem MaralaniH, TaiBC, WongTY, et al.Metabolic syndrome and mortality in the elderly: A time-dependent association. Diabetes Res Clin Pract, 2013; 99:209–216.
12.
KooHS, KimMJ, KimKM, et al.Decreased muscle mass is not an independent risk factor for metabolic syndrome in Korean population aged 70 or older. Clin Endocrinol, 2014; doi: 10.1111/cen.12509.
13.
NakazoneMA, PinheiroA, BraileMC, et al.Prevalence of metabolic syndrome using NCEP-ATPIII and IDF definitions in Brazilian individuals. Rev Assoc Med Bras, 2007; 53:407–413.
14.
SalaroliLB, BarbosaGC, MillJG, et al.Prevalence of metabolic syndrome in population-based study, Vitoria, ES-Brazil. Arq Bras Endocrinol Metabol, 2007; 51:1143–1152.
15.
LindbergA, LarssonLG, MuellerovaH, et al.Up-to-date on mortality in COPD—report from the OLIN COPD study. BMC Pulm Med, 2012; 12:1.
16.
SkybaP, UkropecJ, PobehaP, et al.Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediators Inflamm, 2010; 2010:173498.
